Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance

PURPOSE: Osteosarcoma (OS) mostly affects children and young adults, and has only a 20%–30% 5-year survival rate when metastasized. We aimed to create dual-targeted (extracellular against EphA2 and intracellular against JNK-interacting protein 1 [JIP1]), doxorubicin (DOX)-loaded liposomes to treat O...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghiralsadat, Fateme, Amoabediny, Ghasem, Naderinezhad, Samira, Zandieh-Doulabi, Behrouz, Forouzanfar, Tymour, Helder, Marco N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039070/
https://www.ncbi.nlm.nih.gov/pubmed/30013340
http://dx.doi.org/10.2147/IJN.S150017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039070/
https://www.ncbi.nlm.nih.gov/pubmed/30013340
http://dx.doi.org/10.2147/IJN.S150017

Ejemplares similares